Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
Big Ten Cancer Research Consortium
Bristol-Myers Squibb
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Fondazione Italiana Linfomi - ETS